FI89005B - Foerfarande foer framstaellning av en doseringsform av etodolac med foerdroejd utloesning - Google Patents
Foerfarande foer framstaellning av en doseringsform av etodolac med foerdroejd utloesning Download PDFInfo
- Publication number
- FI89005B FI89005B FI884245A FI884245A FI89005B FI 89005 B FI89005 B FI 89005B FI 884245 A FI884245 A FI 884245A FI 884245 A FI884245 A FI 884245A FI 89005 B FI89005 B FI 89005B
- Authority
- FI
- Finland
- Prior art keywords
- weight
- release
- tablet
- carrier base
- content
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 22
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 20
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 20
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 20
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 17
- 239000002552 dosage form Substances 0.000 claims abstract description 17
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 17
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 17
- 229960005293 etodolac Drugs 0.000 claims abstract description 16
- -1 hydroxypropoxyl Chemical group 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 238000013268 sustained release Methods 0.000 claims abstract description 7
- 239000012730 sustained-release form Substances 0.000 claims abstract description 7
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims abstract description 6
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 12
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 9
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 9
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 2
- 239000007892 solid unit dosage form Substances 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 14
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical group C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013266 extended drug release Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
- Ceramic Products (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (6)
1. Förfarande för framställning av en komposition med fördröjd utlösning, kännetecknat därav, 5 att etodolac blandas med ett bärarbasmaterial och ett ämne som modifierar utlösningshastigheten, varvid bärarbas-materialet är hydroxipropylmetylcellulosa i blandning med etylcellulosa, som utgör 15 - 28 vikt-% av bärarbasmate-rialet, och hydroxipropylmetylcellulosan har ett hydroxi-10 propoxylinnehäll pä 7,0- 8,5 vikt-%, ett metoxylinnehäll pä 19 - 24 vikt-%, viskositeten hos en 2-%:ig vattenlösning är 80 - 120 mPa.s och medelmolekylvikten är mindre än 50 000, varvid ämnet som modifierar utlösningshastigheten utgörs av en effektiv mängd av en fysiologiskt acceptabel buffert-15 syra, buffertsyrasalt, eller en blandning därav, och av att blandningen formas och pressas tili en fast enhetsdosform, vilken har ett regelbundet och fördröjt utlösningsmönster vid administration.
2. Förfarande enligt patentkravet 1, k ä n n e -20 tecknat därav, att man som ämne som modifierar utlösningshastigheten använder natriumdivätefosfat.
3. Förfarande enligt patentkravet 1 eller 2, kännetecknat därav, att det man använder 18 -30 vikt-% bärarbasmaterial av den fasta enhetsdosformen. 25
4. Förfarande enligt patentkravet 3, känne tecknat därav, att man använder 21 - 26,4 vikt-% * - bärarbasmaterial av den fasta enhetsdosformen.
5. Förfarande enligt nägot av de föregäende pa-tentkraven, kännetecknat därav, att viktför- ·.·. 30 hällandet mellan etylcellulosan och hydroxipropylmetylcellulosan i enhetsdosformulationen ärl : 3,2-1 : 4,3.
6. Förfarande enligt nägot av de föregäende pa-tentkraven, kännetecknat därav, att man använder hydroxipropylmetylcellulosa vars hydroxipropoxyl- 3. innehäll är 7,5 - 8,0 vikt-%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10050187A | 1987-09-24 | 1987-09-24 | |
| US10050187 | 1987-09-24 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI884245A0 FI884245A0 (fi) | 1988-09-15 |
| FI884245L FI884245L (fi) | 1989-03-25 |
| FI89005B true FI89005B (fi) | 1993-04-30 |
| FI89005C FI89005C (sv) | 1993-08-10 |
Family
ID=22280080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI884245A FI89005C (sv) | 1987-09-24 | 1988-09-15 | Förfarande för framställning av en doseringsform av etodolac med fördr öjd utlösning |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4966768A (sv) |
| EP (1) | EP0309157B1 (sv) |
| JP (1) | JP2879061B2 (sv) |
| KR (1) | KR960009410B1 (sv) |
| AT (1) | ATE62132T1 (sv) |
| AU (1) | AU613663B2 (sv) |
| CA (1) | CA1318600C (sv) |
| DE (1) | DE3862272D1 (sv) |
| DK (1) | DK168421B1 (sv) |
| ES (1) | ES2021838B3 (sv) |
| FI (1) | FI89005C (sv) |
| GB (1) | GB2209940B (sv) |
| GR (1) | GR3001739T3 (sv) |
| HK (1) | HK41994A (sv) |
| HU (1) | HU200920B (sv) |
| IE (1) | IE60311B1 (sv) |
| IL (1) | IL87757A (sv) |
| MX (1) | MX171463B (sv) |
| PH (1) | PH26146A (sv) |
| PT (1) | PT88564B (sv) |
| ZA (1) | ZA887162B (sv) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993017673A1 (en) * | 1992-03-03 | 1993-09-16 | Top Gold Pty., Limited | Sustained release analgesics |
| US5314697A (en) * | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| US6676967B1 (en) | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US5419917A (en) * | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
| IN182040B (sv) * | 1995-06-13 | 1998-12-12 | American Home Prod | |
| US20030215507A1 (en) * | 1996-03-25 | 2003-11-20 | Wyeth | Extended release formulation |
| US20060068018A1 (en) * | 1996-03-25 | 2006-03-30 | Wyeth | Extended release formulation |
| PE57198A1 (es) | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| US6251430B1 (en) | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
| US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6106862A (en) | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| ATE424810T1 (de) | 1998-12-11 | 2009-03-15 | Nostrum Pharmaceuticals Inc | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung |
| US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| US7151100B1 (en) * | 1999-07-23 | 2006-12-19 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
| IN190974B (sv) * | 1999-09-10 | 2003-09-06 | Ranbaxy Lab Ltd | |
| US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
| CN100478026C (zh) * | 2001-09-28 | 2009-04-15 | 纽特休迪克斯公司 | 用于生物学组分的传递系统 |
| US20070098784A1 (en) * | 2001-09-28 | 2007-05-03 | Nutraceutix, Inc. | Delivery system for biological component |
| DE20220415U1 (de) * | 2001-11-07 | 2003-10-09 | Synthon Bv | Tamsulosin-Tabletten |
| IL146462A (en) * | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
| WO2003057198A1 (fr) * | 2002-01-09 | 2003-07-17 | Ucb, S.A. | Compositions pharmaceutiques a liberation modifiee |
| EP2316469A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| AU2003295336A1 (en) * | 2002-09-19 | 2004-04-08 | Dennis A. Carson | Use of etodoclac to treat hyperplasia |
| US6703044B1 (en) | 2002-10-25 | 2004-03-09 | Dexcel Pharma Tech, Ltd | Venlafaxine formulations |
| US7018658B2 (en) * | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
| US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| WO2004112756A1 (en) | 2003-06-26 | 2004-12-29 | Isa Odidi | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US20050106253A1 (en) * | 2003-11-13 | 2005-05-19 | Platteeuw Johannes J. | Pharmaceutical pellets comprising tamsulosin |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| CN101453993A (zh) | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
| EP2010158B1 (en) * | 2006-04-26 | 2016-02-17 | Alphapharm Pty Ltd. | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| WO2007131804A1 (en) | 2006-05-17 | 2007-11-22 | Synthon B.V. | Tablet composition with a prolonged release of tamsulosin |
| US8465770B2 (en) | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
| TR200908308A1 (tr) | 2010-01-18 | 2011-08-22 | Turgut İlaçlari A.Ş. | Etodolak içeren sürekli salım tablet formulasyonu |
| CN102485215B (zh) * | 2010-12-03 | 2013-05-15 | 沈阳药科大学 | 依托度酸定时释药微丸制剂及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939178A (en) * | 1971-06-01 | 1976-02-17 | American Home Products Corporation | Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles |
| GB1468172A (en) * | 1973-03-28 | 1977-03-23 | Benzon As Alfred | Oral drug preparations |
| US3954959A (en) * | 1973-03-28 | 1976-05-04 | A/S Alfred Benzon | Oral drug preparations |
| US4309406A (en) * | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4533551A (en) * | 1984-02-17 | 1985-08-06 | American Home Products Corporation | Method of treating arthritis with etodolac |
| US4657757A (en) * | 1985-03-29 | 1987-04-14 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
-
1988
- 1988-09-07 IE IE270988A patent/IE60311B1/en not_active IP Right Cessation
- 1988-09-09 CA CA000576957A patent/CA1318600C/en not_active Expired - Lifetime
- 1988-09-13 AU AU22153/88A patent/AU613663B2/en not_active Expired
- 1988-09-15 FI FI884245A patent/FI89005C/sv not_active IP Right Cessation
- 1988-09-15 IL IL87757A patent/IL87757A/xx active Protection Beyond IP Right Term
- 1988-09-16 GB GB8821749A patent/GB2209940B/en not_active Expired - Lifetime
- 1988-09-16 EP EP88308564A patent/EP0309157B1/en not_active Expired - Lifetime
- 1988-09-16 DE DE8888308564T patent/DE3862272D1/de not_active Expired - Lifetime
- 1988-09-16 ES ES88308564T patent/ES2021838B3/es not_active Expired - Lifetime
- 1988-09-16 AT AT88308564T patent/ATE62132T1/de not_active IP Right Cessation
- 1988-09-17 JP JP63233366A patent/JP2879061B2/ja not_active Expired - Lifetime
- 1988-09-21 PT PT88564A patent/PT88564B/pt not_active IP Right Cessation
- 1988-09-21 MX MX013091A patent/MX171463B/es unknown
- 1988-09-23 ZA ZA887162A patent/ZA887162B/xx unknown
- 1988-09-23 HU HU884992A patent/HU200920B/hu unknown
- 1988-09-23 KR KR88012298A patent/KR960009410B1/ko not_active Expired - Lifetime
- 1988-09-23 PH PH37584A patent/PH26146A/en unknown
- 1988-09-23 DK DK531088A patent/DK168421B1/da not_active IP Right Cessation
- 1988-11-07 US US07/268,646 patent/US4966768A/en not_active Expired - Lifetime
-
1991
- 1991-04-04 GR GR91400364T patent/GR3001739T3/el unknown
-
1994
- 1994-04-28 HK HK41994A patent/HK41994A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA1318600C (en) | 1993-06-01 |
| IL87757A0 (en) | 1989-02-28 |
| ZA887162B (en) | 1990-05-30 |
| KR890004686A (ko) | 1989-05-09 |
| GB2209940A (en) | 1989-06-01 |
| EP0309157A1 (en) | 1989-03-29 |
| GB2209940B (en) | 1991-08-14 |
| MX171463B (es) | 1993-10-28 |
| KR960009410B1 (en) | 1996-07-19 |
| EP0309157B1 (en) | 1991-04-03 |
| JPH02270820A (ja) | 1990-11-05 |
| US4966768A (en) | 1990-10-30 |
| DK531088D0 (da) | 1988-09-23 |
| ATE62132T1 (de) | 1991-04-15 |
| AU613663B2 (en) | 1991-08-08 |
| IE882709L (en) | 1989-03-24 |
| DE3862272D1 (de) | 1991-05-08 |
| JP2879061B2 (ja) | 1999-04-05 |
| HUT50631A (en) | 1990-03-28 |
| PH26146A (en) | 1992-03-18 |
| DK531088A (da) | 1989-03-25 |
| GR3001739T3 (en) | 1992-11-23 |
| PT88564A (pt) | 1988-10-01 |
| ES2021838B3 (es) | 1991-11-16 |
| DK168421B1 (da) | 1994-03-28 |
| IL87757A (en) | 1992-06-21 |
| GB8821749D0 (en) | 1988-10-19 |
| IE60311B1 (en) | 1994-06-29 |
| HK41994A (en) | 1994-05-06 |
| PT88564B (pt) | 1992-11-30 |
| FI89005C (sv) | 1993-08-10 |
| AU2215388A (en) | 1989-05-11 |
| FI884245L (fi) | 1989-03-25 |
| HU200920B (en) | 1990-09-28 |
| FI884245A0 (fi) | 1988-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI89005B (fi) | Foerfarande foer framstaellning av en doseringsform av etodolac med foerdroejd utloesning | |
| FI83037B (fi) | Foerfarande foer framstaellning av en naproxen och natrium naproxentablett med styrd utloesning. | |
| EP1340495B1 (en) | Extended release tablet of clarithromycin | |
| US4248856A (en) | Sustained release pharmaceutical compositions | |
| US4248858A (en) | Sustained release pharmaceutical compositions | |
| US7943170B2 (en) | Sustained release paracetamol containing compositions | |
| KR101774676B1 (ko) | 히드로모르폰 및 날록손을 포함하는 제약 조성물 | |
| BG64168B1 (bg) | Бързоразтворима таблета на галантамин хидробромид | |
| HU197839B (en) | Process for producing metoprolol containing pharmaceutical compositions | |
| US12502384B2 (en) | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | |
| US5047247A (en) | Dispersible tablets of dihydroergotoxine methanesulfonate and of acid addition salts thereof | |
| JP3110794B2 (ja) | １，４−ジヒドロピリジン誘導体を含有する製剤 | |
| US8105627B2 (en) | Extended release venlafaxine tablet formulation | |
| US5853756A (en) | Controlled release formulations of Ranitidine | |
| PL191767B1 (pl) | Stabilizowane przed racemizacją stałe lub ciekłe preparaty farmaceutyczne zawierające jako składnik czynny cilansetron, sposób wytwarzania stabilizowanych przed racemizacją stałych preparatów farmaceutycznych zawierających jako składnik czynny cilansetron oraz zastosowanie dopuszczalnych fizjologicznie rozpuszczalnych w wodzie kwaśnych dodatków | |
| KR20240024979A (ko) | 난용성 약물의 삼투압 펌프 제어 방출 정제 및 그의 제조방법 | |
| EP2043612B1 (en) | A stable olanzapine formulation with antioxidants | |
| JPH0236571B2 (ja) | Jizokuseiseizai | |
| AU2016243691A1 (en) | Combination dosage form of a mu opioid receptor antagonist and an opioid agent | |
| JPH0466846B2 (sv) | ||
| HK1027023B (en) | Extended release formulations of clarithromycin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| FG | Patent granted |
Owner name: WYETH |
|
| MA | Patent expired |